Latest News

Darovasertib plus crizotinib boosts survival signals and response rates in HLA-A2–negative metastatic uveal melanoma, with manageable safety.

SERENA-6 shows early switch to oral SERD camizestrant plus CDK4/6 inhibitor improves PFS2, delays chemotherapy, and preserves quality of life.

The FDA granted Priority Review to the NDA for bezuclastinib plus sunitinib in previously treated advanced gastrointestinal stromal tumors (GIST).

Apnimed has submitted an NDA for AD109 for obstructive sleep apnea following positive phase 3 results from the SynAIRgy and LunAIRo trials.

A real-world study presented at ASCO 2026 found that early intravenous immunoglobulin administration within 4 weeks of starting talquetamab was associated with significantly lower infection rates and reduced 1-year mortality in patients with relapsed or refractory multiple myeloma.

Recent developments reflect a broader shift toward individualized, biologically informed care.

As retatrutide moves toward FDA submission, Jennifer Goldman, PharmD, breaks down the TRIUMPH-1 data—and what it means for patient selection, dose escalation counseling, and positioning within the antiobesity pipeline.

Updated results from a phase 1 study showed that KLN-1010 produced reduced MRD-negative responses in all treated patients with RRMM.

Data presented at ASCO 2026 show giredestrant plus palbociclib extends PFS in ER+/HER2– metastatic breast cancer; FDA approval on the horizon.

ASCENT-04 updated data show sacituzumab govitecan plus pembrolizumab extends benefit past progression in PD-L1+ metastatic TNBC.

Final results from the CEPHEUS trial showed that daratumumab plus VRd produced deeper, more durable responses and prolonged survival.

Emerging evidence suggests that some individuals develop nutritional deficiencies during treatment, while others experience biologically driven GLP-1 resistance.

An RNA- and lipid nanoparticle–based platform derived from non-LTR transposons enables stable in vivo CAR T-cell engineering.

Disparities in education access and quality, income level, and race and ethnicity are SDoH that make a major impact on diabetes and its management in the US.

ASCO 2026: Daraxonrasib boosts survival and PFS in metastatic pancreatic cancer versus chemo, with better tolerability and quality-of-life preservation.

ASCO 2026 data show encorafenib plus cetuximab with FOLFIRI boosts response and PFS in BRAF V600E mCRC, complementing FOLFOX.

Findings presented at the 2026 Joint ASTCT + EBMT Basic and Translational Scientific Meeting offer potential therapeutic targets to reduce GI toxicity and GVHD.

With no new kidney-protective therapies approved in T1D for over three decades, experts break down the clinical significance of finerenone's FDA priority review and what pharmacists need to know.

Phase 3 SARC041 shows abemaciclib sharply extends progression-free survival in advanced dedifferentiated liposarcoma, hinting at a new standard.

The trial met both dual primary end points of pathologic complete response and metastasis-free survival.